Johnson & Johnson (JNJ)
259.77
-4.97 (-1.88%)
NYSE · Last Trade: Oct 1st, 2:57 PM EDT
Detailed Quote
| Previous Close | 264.74 |
|---|---|
| Open | 263.68 |
| Bid | 259.73 |
| Ask | 259.81 |
| Day's Range | 258.33 - 263.98 |
| 52 Week Range | 181.07 - 281.07 |
| Volume | 3,757,019 |
| Market Cap | 682.85B |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | 5.360 (2.06%) |
| 1 Month Average Volume | 6,382,814 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
These dow jones stocks are moving in today's sessionchartmill.com
Via Chartmill · October 1, 2026
Jabil posted a double-beat quarter with nearly 29% revenue growth and 34% EPS growth, driven by AI demand, while maintaining buybacks and a Buy-rated analyst consensus.
Via MarketBeat · October 1, 2026
Medtronic is following a strategy that has worked well for Johnson & Johnson.
Via The Motley Fool · October 1, 2026
Johnson & Johnson (NYSE: JNJ) today released new findings that show most women know menopause can affect mood and sleep, but fewer than half realize their eye health may change too. A new global survey of 6,000 women found that only 40% connect eye changes with the menopause transition—even though 90% say seeing clearly and comfortably helps them feel confident, capable or like themselves.i
By Johnson & Johnson · Via Business Wire · October 1, 2026
Analysts think this beaten-down healthcare stock will rebound.
Via The Motley Fool · October 1, 2026
New investors might be eager to jump in during a bull market.
Via The Motley Fool · October 1, 2026
This is not an exhaustive list.
Via The Motley Fool · September 30, 2026
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
Via MarketBeat · September 30, 2026
SHCD is missing some of the healthiest dividend stocks.
Via The Motley Fool · September 30, 2026
Which dow jones stocks are moving on Tuesday?chartmill.com
Via Chartmill · September 29, 2026
Uncover the latest developments among dow jones stocks in today's session.chartmill.com
Via Chartmill · September 29, 2026
Top dow jones movers in Monday's sessionchartmill.com
Via Chartmill · September 28, 2026
Uncover the latest developments among dow jones stocks in today's session.chartmill.com
Via Chartmill · September 28, 2026
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
Via The Motley Fool · September 25, 2026
Friday's session: top gainers and losers in the dow jones indexchartmill.com
Via Chartmill · September 25, 2026
Stay informed with the top movers within the dow jones index on Thursday.chartmill.com
Via Chartmill · September 24, 2026
Thursday's session: top gainers and losers in the dow jones indexchartmill.com
Via Chartmill · September 24, 2026
The next bear market may be your best opportunity to grow your portfolio.
Via The Motley Fool · September 24, 2026
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
Via The Motley Fool · September 24, 2026
Wall Street thinks that this robotic surgical systems leader's sell-off is overdone.
Via The Motley Fool · September 24, 2026
You can take these companies' dividends straight to the bank.
Via The Motley Fool · September 23, 2026
DePuy Synthes, a global leader in orthopaedic technologies and solutions, will showcase its latest trauma innovations at the 2026 Orthopaedic Trauma Association (OTA) Annual Meeting in Nashville, including four new VOLT™ plating systems, MAXFRAME AUTOSTRUT™ with Bluetooth® Multi-Axial Correction System, VELYS™ Trauma AI Assisted Surgery enabling technology, and an expanded value offering for procedural solutions.
By DePuy Synthes · Via Business Wire · September 22, 2026
Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.
Via The Motley Fool · September 21, 2026
It may not be possible to avoid all risks, but it's certainly possible to minimize them.
Via The Motley Fool · September 21, 2026
The unlocking of SpaceX shares is reshaping the communications sector.
Via The Motley Fool · September 20, 2026
